B36 topoisomerase inhibitors and mitotic spindle inhibitors Flashcards
What are the anthracycline drugs?
‘-rubicins’
rubies on the sunken pirate ship
Doxorubicin - most widely used one. very common cancer drug.
Daunorubicin
Idarubicin
Idarubicin
Epirubicin
MoA of the anthracyclines
Multiple mechanisms:
1) Form free radicals, superoxides and hydrogen peroxides, which can directly oxidize phosphodiester bonds, or any other molecules in the cell. Lipid peroxidation.
2) Interchelate in the DNA and form a stable bond with DNA-Topoisomerase 2 complex, after it has cut both DNA strands, preventing annealing.
They are NOT cycle specific, can kill anytime.
Main Anthracycline drug, and its indications
Doxorubicin.
Very widely used, for many solid and hematologic tumors.
Doxorubicin
Kinetics and SEs
Doxorubicin, and all of the anthracyclines must be given I.V.
They Do NOT penetrate to the CNS or to the testes.
Metabolized by the liver, and excreted mostly in bile must be adjusted if liver is impaired.
Minor excretion in the urine.
SEs:
- Extravasation and necrosis at the injection site.
- Red urinary discoloration (from drug excretion)
- Irreversible Dialative Cardiomyopathy
- Marrow depletion
What agent is used to lessen/prevent the worst side effect of Doxorubicin?
Dexrazoxane
Dex Razox Ane
Daunorubicin indication
Acute luekemias
Mitoxantrone class and indication
Anthracycline, for prostate cancer.
What are the anthracyclines that have the least cardiotoxicity?
Idarubicin and Epirubicin
Liposomal encased doxorubicin also has lowered tox.
What drugs inhibit Topo 1
The camptothecins -
Camptothecin
Topotecan
Irinotecan
Topo2 inhibitors
Etoposide and Teniposide
Etoposide
MoA
Inhibits Topo2, stabilizing double strand break
Cells accumulate in late S, G2 phase
Etoposide indications
Lung cancer
Hodgkins and non Hodkins lymphoma
Testicular cancer
Topotecan Rx
Ovarian cancer
Small cell lung cancer
Irenotecan Rx
Colon cancer
Camptothecins
MoA
SEs
Inhibit Topo1
Cells accumulate in S-phase
SEs;
myelosuppression,
diarrhea
severe, late onset diarrhea with irenotecan, 2-10 days after treatment. Can cause severe dehydration or ion loss.